Highlights from the 63rd American Society of Hematology (ASH) Annual Meeting
J Clin Pathways. 2022;8;(1):10-15.
Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel for Relapsed or Refractory LBCL
Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.
First-Line Venetoclax Plus Azacitidine vs Intensive Chemotherapy for Patients With AML in the Real-World Setting
In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.
Real-World Treatment Patterns and Decision-Making for Patients With MM in the United States
Study results presented at the 2021 ASH Annual Meeting provide valuable real-world data on current treatment patterns and decision-making for patients with MM.
Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Real-World Safety, Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM
In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with MM to those seen in clinical trials.
